Canada-Approved Medicine

This monograph describes a medication approved for use in Canada by the Therapeutic Products Directorate, a division of Health Canada’s Health Products and Food Branch. The medication is not approved by the United States Food and Drug Administration; however, a similar formulation carrying a different generic or brand name might be available in the US.


Trade Name(s)

  • Modulon Canadian Trade name

Ther. Class.

lower gastrointestinal tract motility regulators



  • Symptomatic treatment of irritable bowel syndrome (IBS).
  • Treatment of postoperative paralytic ileus.


Acts as a spasmolytic.

Therapeutic Effect(s):

  • ↓ symptoms of IBS.
  • Resumption of intestinal transit following abdominal surgical procedures.


Absorption: Rapidly absorbed following oral administration.

Distribution: Unknown.

Metabolism and Excretion: Extensively metabolized, <2.4% excreted unchanged in urine.

Half-life: 2.7–3.1 hr.

TIME/ACTION PROFILE (symptom relief)

POwithin 3 days–2 wk1 hr (blood level)>1 wk (following discontinuation)


Contraindicated in:

  • Hypersensitivity.

Use Cautiously in:

  • OB:  Not recommended for use;
  • Pedi:   Children <12 yr (safety and effectiveness not established).

Adverse Reactions/Side Effects

CNS: dizziness, drowsiness, fatigue, headache

GI: diarrhea, dry mouth, dysguesia, dyspepsia, epigastric pain, nausea

Derm: hot/cold sensation, rash

* CAPITALS indicate life-threatening.
Underline indicate most frequent.



None known


PO (Adults): 200 mg 3 times daily.


Tablets: 100 mg, 200 mg


  • Assess for symptoms of irritable bowel syndrome (cramping, constipation and diarrhea, mucus in stools).
  • Assess for abdominal distention and assess bowel sounds.
  • Monitor intake and output and record.

Potential Diagnoses


  • PO Administer three times daily before meals.

Patient/Family Teaching

  • Instruct patient to take trimebutine as directed.
  • Advise female patient to inform health care professional if pregnancy is planned or suspected or if breast feeding.

Evaluation/Desired Outcomes

Decrease signs and symptoms of irritable bowel disease.

trimebutine is a sample topic from the Davis's Drug Guide.

To view other topics, please or .

Anesthesia Central is an all-in-one web and mobile solution for treating patients before, during, and after surgery. This collection of drugs, procedures, and test information is derived from Davis’s Drug, MGH Clinical Anesthesia Procedures, Pocket Guide to Diagnostic Tests, and PRIME Journals. .